IndiaMart
FIEO
FOXO4 10mg is a synthetic peptide derived from the FOXO4 transcription factor, widely studied for its senolytic properties and ability to target senescent cells. It is a critical compound in aging research, regenerative medicine, and cellular biology studies, showing potential in promoting tissue regeneration and delaying age-related cellular dysfunction.
By selectively targeting FOXO4-p53 interactions, FOXO4 10mg has been shown in research to induce apoptosis in senescent cells, thereby restoring cellular function and improving tissue homeostasis. This makes it a valuable tool in anti-aging research, neurodegenerative studies, and regenerative therapies.
BLUEPILL EXPRESS, a global merchant exporter, supplies FOXO4 10mg manufactured in GMP-certified facilities in India and China, based on client requirements and regulatory compliance. Each batch undergoes rigorous HPLC and mass spectrometry testing to ensure purity, stability, and bioactivity, making it suitable for high-level research applications.
Key Features of FOXO4 10mg:
- High-purity senolytic peptide for cellular aging and regenerative research
- Targets senescent cells and promotes tissue homeostasis
- Used in studies on aging, neurodegeneration, and cellular regeneration
- Manufactured under GMP-certified conditions in India and China
- Supplied worldwide by BLUEPILL EXPRESS – Merchant Exporter
- Delivered with COA, MSDS, and full export documentation
- Available for bulk, OEM, and private-label supply
- Ideal for biomedical, pharmaceutical, and regenerative medicine research
- Verified for bioactivity, purity, and consistent research-grade quality
As a leading merchant exporter, BLUEPILL EXPRESS specializes in research peptides, senolytic compounds, and bioactive molecules, including FOXO4 10mg, Epithalon, BPC157, TB500, CJC-1295, and Semaglutide. With manufacturing facilities in India and China, the company ensures customized production, international regulatory compliance, and reliable global shipping, serving researchers, biotech firms, and pharmaceutical developers worldwide.
